Field Suitability and Diagnostic Accuracy of the Biocentric Open Real-Time PCR Platform for Dried Blood Spot-Based HIV Viral Load Quantification in Eswatini.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 09 2019
01 09 2019
Historique:
entrez:
14
8
2019
pubmed:
14
8
2019
medline:
15
4
2020
Statut:
ppublish
Résumé
To assess the performance and suitability of dried blood spot (DBS) sampling using filter paper to collect blood for viral load (VL) quantification under routine conditions. We compared performance of DBS VL quantification using the Biocentric method with plasma VL quantification using Roche and Biocentric as reference methods. Adults (≥18 years) were enrolled at 2 health facilities in Eswatini from October 12, 2016 to March 1, 2017. DBS samples were prepared through finger-prick by a phlebotomist (DBS-1), and through the pipetting of whole venous blood by a phlebotomist (DBS-2) and by a laboratory technologist (DBS-3). We calculated the VL-testing completion rate, correlation, and agreement, as well as diagnostic accuracy estimates at the clinical threshold of 1000 copies/mL. Of 362 patients enrolled, 1066 DBS cards (DBS-1: 347; DBS-2: 359; DBS-3: 360) were tested. Overall, test characteristics were comparable between DBS-sampling methods, irrespective of the reference method. The Pearson correlation coefficients ranged from 0.67 to 0.82 (P < 0.001) for different types of DBS sampling using both reference methods, and the Bland-Altman difference ranged from 0.15 to 0.30 log10 copies/mL. Sensitivity estimates were from 85.3% to 89.2% and specificity estimates were from 94.5% to 98.6%. The positive predictive values were between 87.0% and 96.5% at a prevalence of 30% VL elevations, and negative predictive values were between 93.7% and 95.4%. DBS VL quantification using the newly configured Biocentric method can be part of contextualized VL-testing strategies, particularly for remote settings and populations with higher viral failure rates.
Sections du résumé
BACKGROUND
To assess the performance and suitability of dried blood spot (DBS) sampling using filter paper to collect blood for viral load (VL) quantification under routine conditions.
METHODS
We compared performance of DBS VL quantification using the Biocentric method with plasma VL quantification using Roche and Biocentric as reference methods. Adults (≥18 years) were enrolled at 2 health facilities in Eswatini from October 12, 2016 to March 1, 2017. DBS samples were prepared through finger-prick by a phlebotomist (DBS-1), and through the pipetting of whole venous blood by a phlebotomist (DBS-2) and by a laboratory technologist (DBS-3). We calculated the VL-testing completion rate, correlation, and agreement, as well as diagnostic accuracy estimates at the clinical threshold of 1000 copies/mL.
RESULTS
Of 362 patients enrolled, 1066 DBS cards (DBS-1: 347; DBS-2: 359; DBS-3: 360) were tested. Overall, test characteristics were comparable between DBS-sampling methods, irrespective of the reference method. The Pearson correlation coefficients ranged from 0.67 to 0.82 (P < 0.001) for different types of DBS sampling using both reference methods, and the Bland-Altman difference ranged from 0.15 to 0.30 log10 copies/mL. Sensitivity estimates were from 85.3% to 89.2% and specificity estimates were from 94.5% to 98.6%. The positive predictive values were between 87.0% and 96.5% at a prevalence of 30% VL elevations, and negative predictive values were between 93.7% and 95.4%.
CONCLUSIONS
DBS VL quantification using the newly configured Biocentric method can be part of contextualized VL-testing strategies, particularly for remote settings and populations with higher viral failure rates.
Identifiants
pubmed: 31408452
doi: 10.1097/QAI.0000000000002101
pii: 00126334-201909010-00014
pmc: PMC6727953
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-104Références
J Clin Microbiol. 2003 May;41(5):1888-93
pubmed: 12734222
J Clin Microbiol. 2016 Jun;54(6):1641-1643
pubmed: 27008874
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):319-329
pubmed: 28708808
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
MMWR Morb Mortal Wkly Rep. 2016 Dec 02;65(47):1332-1335
pubmed: 27906910
J Clin Microbiol. 2009 Apr;47(4):1107-18
pubmed: 19193835
Clin Infect Dis. 2016 Apr 15;62(8):1043-8
pubmed: 26743094
Expert Opin Med Diagn. 2011 May;5(3):183-202
pubmed: 23484497
J Virol Methods. 2009 Oct;161(1):177-80
pubmed: 19523984
Arch Med Res. 2005 Jul-Aug;36(4):382-6
pubmed: 15950079
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):45-51
pubmed: 24872139
Expert Rev Mol Diagn. 2008 Sep;8(5):635-50
pubmed: 18785811
J Antimicrob Chemother. 2010 Aug;65(8):1562-6
pubmed: 20542904
J Virol Methods. 2010 Feb;163(2):489-91
pubmed: 19878694
J Clin Microbiol. 2012 Nov;50(11):3614-9
pubmed: 22952265
PLoS One. 2017 Jul 13;12(7):e0181054
pubmed: 28704560
AIDS Res Ther. 2017 Jan 19;14(1):3
pubmed: 28103895
PLoS One. 2015 Feb 19;10(2):e0116144
pubmed: 25695494
J Clin Microbiol. 2019 Mar 28;57(4):
pubmed: 30728197
J Virol Methods. 2007 Dec;146(1-2):178-87
pubmed: 17686534
J Clin Microbiol. 2014 Nov;52(11):3878-83
pubmed: 25143579
J Clin Microbiol. 2012 Mar;50(3):831-6
pubmed: 22170927
Virol J. 2017 Nov 14;14(1):224
pubmed: 29137673
J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):590-3
pubmed: 18193501
PLoS One. 2018 Sep 19;13(9):e0201341
pubmed: 30231022
J Virol Methods. 2008 Mar;148(1-2):291-5
pubmed: 18242718
J Infect. 2015 Sep;71(3):368-76
pubmed: 26033694
Medicine (Baltimore). 2016 Nov;95(48):e5475
pubmed: 27902602
PLoS One. 2014 Mar 06;9(3):e86461
pubmed: 24603442
J Clin Microbiol. 2016 Aug;54(8):2104-8
pubmed: 27252459
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):380-8
pubmed: 17468666
J Clin Microbiol. 2014 Feb;52(2):578-86
pubmed: 24478491
BMC Infect Dis. 2018 Nov 14;18(1):570
pubmed: 30428850
J Acquir Immune Defic Syndr. 2010 Nov;55(3):290-8
pubmed: 20700058
J Virol Methods. 2018 Jan;251:75-79
pubmed: 29038002
AIDS. 2014 Mar;28 Suppl 2:S151-60
pubmed: 24849475
J Clin Microbiol. 2019 Mar 28;57(4):
pubmed: 30700508
J Int AIDS Soc. 2015 Jul 23;18:20090
pubmed: 26208630
J Acquir Immune Defic Syndr. 2017 Apr 01;74(4):399-406
pubmed: 28002185
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29171172